MenuClose
ESMO 2026On demandMadrid, October 23–27See the ESMO 2026 highlightsSubscribe to the newsletter

Recent coverage

ESMO 2026On demandMadrid, October 23–27See the ESMO 2026 highlights

More tumor sites

Across disciplines

NADIM: five-year outcomesPerioperative chemotherapy plus nivolumab in resectable stage IIIA NSCLC: 5-year progression-free survival of 65%.Latest highlight, from The Lancet Oncology

The 2026 program

The OncoAlert Colloquium emblemThe OncoAlert ColloquiumThe year in review in oncology, one tumor group a day. Free for oncology professionals.

Listen to Oncology Here & Now

The newest Horizons discussionAdjuvant treatment challenges in early HR+/HER2− breast cancer, with Dr. Sibylle Loibl and Dr. Rupert Bartsch.

ESMO 2026 Top 10 trials to watch

Madrid, October 23–27, 2026

All ESMO 2026 highlights

Top 10 trials to watch

For each tumor group, the ten trials our faculty were watching in Madrid.

Choose a tumor group
  1. Abstract LBA50PANKU-BREAST01Izalontamab brengitecan (IZA-BREN) in previously treated unresectable locally advanced or metastatic HR+/HER2− breast cancer. Randomized phase 3 study.
  2. Abstract 1842OFOURLIGHT-1Atirmociclib plus fulvestrant in HR+/HER2− advanced or metastatic breast cancer following progression on a prior CDK4/6 inhibitor. Randomized phase 2 study.
  3. Abstract LBA25NATALEEAdjuvant ribociclib plus a nonsteroidal aromatase inhibitor in HR+/HER2− early breast cancer. Six-year overall survival and efficacy outcomes.
  4. Abstract LBA27APEX-BREAST01TQB2102 versus chemotherapy in HER2-low recurrent or metastatic breast cancer. Randomized phase 3 study.
  5. Abstract LBA51KEYNOTE-B49Pembrolizumab versus placebo, both combined with chemotherapy, in HR+/HER2− advanced breast cancer. Randomized, double-blind phase 3 study.
  6. Abstract LBA13HORIZON-BREAST06Trastuzumab rezetecan (SHR-A1811) in HER2-low advanced breast cancer. Randomized phase 3 study.
  7. Abstract LBA26POP-DURVAShort-term preoperative durvalumab for stage I triple-negative breast cancer (TNBC). First results from the phase 2 UNLOCK 14 study.
  8. Abstract 4ROSWITCHTarget switching with conserved-payload novel antibody-drug conjugates (ADCs) in metastatic breast cancer following prior ADC therapy. Prospective, open-label phase 2 platform trial.
  9. Abstract 1ROpostMONARCHAbemaciclib plus fulvestrant versus placebo plus fulvestrant in HR+/HER2− advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy. Phase 3 overall survival results.
  10. Abstract LBA49DESTINY-Breast09Trastuzumab deruxtecan plus pertuzumab versus taxane plus trastuzumab plus pertuzumab in HER2+ advanced or metastatic breast cancer with baseline brain metastases. DESTINY-Breast09 analysis.